Description
Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
Article: Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
€2.42
Related products
-
Article: Highlights in breast cancer
€2.42 Add to cart -
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€147.15 Add to cart -
Article: Highlights in breast cancer
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart
